Maravai LifeSciences (NASDAQ:MRVI) Stock Moved Up to Buy by Wall Street Zen

Key Points

• Wall Street Zen upgraded Maravai LifeSciences from “hold” to “buy.” Analysts’ overall consensus is “Moderate Buy,” with an average price target of $7.38.
• Recent analyst views are mixed: price targets include $8 from UBS, $6.50 from Wells Fargo, and $9 from TD Cowen, while Weiss Ratings maintained a “sell” rating.
• Maravai reported quarterly revenue of $45.85 million and a loss of $0.03 per share, beating consensus estimates of $43.56 million in revenue and a $0.06 per-share loss.

Maravai LifeSciences (NASDAQ:MRVI - Get Free Report) was upgraded by investment analysts at Wall Street Zen from a "hold" rating to a "buy" rating in a research report issued on Saturday, Wall Street Zen reports.

A number of other equities analysts have also commented on MRVI. UBS Group raised their price objective on Maravai LifeSciences from $2.50 to $8.00 and gave the stock a "neutral" rating in a research note on Wednesday, September 9th. Wells Fargo & Company upped their target price on shares of Maravai LifeSciences from $5.50 to $6.50 and gave the company an "overweight" rating in a research report on Friday, August 7th. TD Cowen initiated coverage on shares of Maravai LifeSciences in a report on Monday, October 5th. They issued a "buy" rating and a $9.00 price objective on the stock. Finally, Weiss Ratings reaffirmed a "sell (d-)" rating on shares of Maravai LifeSciences in a research report on Wednesday, August 26th. One equities research analyst has rated the stock with a Strong Buy rating, two have given a Buy rating, one has given a Hold rating and one has assigned a Sell rating to the stock. According to MarketBeat, Maravai LifeSciences has a consensus rating of "Moderate Buy" and an average target price of $7.38.

Maravai LifeSciences Price Performance

Shares of NASDAQ MRVI opened at $7.52 on Friday. The firm's 50-day simple moving average is $7.37 and its 200 day simple moving average is $5.33. The stock has a market cap of $1.95 billion, a price-to-earnings ratio of -17.49 and a beta of 0.61. Maravai LifeSciences has a fifty-two week low of $2.55 and a fifty-two week high of $9.42. The company has a debt-to-equity ratio of 0.49, a quick ratio of 2.98 and a current ratio of 4.05.

Maravai LifeSciences (NASDAQ:MRVI - Get Free Report) last announced its quarterly earnings data on Wednesday, November 4th. The company reported ($0.03) EPS for the quarter, beating the consensus estimate of ($0.06) by $0.03. Maravai LifeSciences had a negative net margin of 37.07% and a negative return on equity of 15.70%. The firm had revenue of $45.85 million for the quarter, compared to the consensus estimate of $43.56 million. As a group, research analysts anticipate that Maravai LifeSciences will post -0.18 earnings per share for the current fiscal year.

Institutional Inflows and Outflows

A number of large investors have recently modified their holdings of MRVI. Dimensional Fund Advisors LP grew its holdings in shares of Maravai LifeSciences by 64.8% in the first quarter. Dimensional Fund Advisors LP now owns 1,418,597 shares of the company's stock valued at $4,015,000 after acquiring an additional 558,050 shares in the last quarter. Bank of New York Mellon Corp bought a new stake in shares of Maravai LifeSciences during the 2nd quarter worth approximately $2,230,000. Brummer Multi Strategy AB grew its holdings in Maravai LifeSciences by 66.0% in the first quarter. Brummer Multi Strategy AB now owns 759,743 shares of the company's stock worth $2,150,000 after purchasing an additional 302,036 shares during the last quarter. Headlands Technologies LLC purchased a new position in Maravai LifeSciences in the second quarter valued at $1,038,000. Finally, General American Investors Co. Inc. increased its stake in shares of Maravai LifeSciences by 8.3% in the 1st quarter. General American Investors Co. Inc. now owns 1,716,193 shares of the company's stock worth $4,857,000 after acquiring an additional 130,877 shares during the last quarter. 50.25% of the stock is currently owned by institutional investors.

Maravai LifeSciences Company Profile

Maravai LifeSciences Holdings, Inc is a life sciences company that provides products and services used in the development, manufacture and quality testing of biopharmaceuticals, vaccines and diagnostic products. The company serves pharmaceutical, biotechnology, academic and other research organizations involved in nucleic acid and biologics development.

Through its TriLink BioTechnologies business, Maravai supplies specialized nucleic acid products and services, including modified nucleotides, messenger RNA-related materials, enzymes and other components used in research and biomanufacturing.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.